Investment Rating - The report maintains an investment rating of "Outperform" [4] Core Insights - The innovative drug sector is experiencing a surge in business development (BD) transactions, with expectations for multiple BD deals to emerge in Q4 2025. As of October 2025, there have been 175 overseas licensing BD transactions in the domestic innovative drug sector, with a total contract value of $104.2 billion and upfront payments reaching $8.1 billion, surpassing the total figures for the entire year of 2024 [2][17][18]. Summary by Sections Weekly New Drug Market Review - From November 10 to November 16, 2025, the top five gainers in the new drug sector were: - Gilead Sciences (+45.40%) - Lai Kai Pharmaceutical (+27.93%) - Jiahe Biopharma (+24.61%) - Zhongsheng Pharmaceutical (+24.46%) - Kaitu Pharmaceutical (+22.81%) - The top five losers were: - Yongtai Biopharma (-7.74%) - Junsheng Tai (-7.43%) - Weixin Biopharma (-1.87%) - Zai Ding Pharmaceutical (-0.93%) - Maibo Pharmaceutical (-0.00%) [1][13][15] Recommended Focus Stocks - The report suggests focusing on several stocks with potential catalysts, including: 1. Products with high overseas sales certainty certified by MNCs: - PD-1 upgraded product: Sanofi - GLP-1 asset: Lianbang Pharmaceutical - ADC asset: Kelun-Botai 2. Potential heavyweights for overseas licensing from MNCs: - PD-1 upgraded product: Kangfang Biopharma - Breakthroughs in autoimmune fields: Yifang Biopharma, China Antibody - Innovative target ADC: Fuhong Hanlin, Shiyao Group 3. Stocks likely to benefit from medical insurance negotiations and commercial insurance innovative drug directories: - Expected beneficiaries from medical insurance directory: Hengrui Medicine, Kangnuo Pharmaceutical, Maiwei Biopharma, Zhixiang Jintai, Haichuang Pharmaceutical - Expected beneficiaries from commercial insurance innovative drug directory: WuXi AppTec, Kexin Pharmaceutical [2][17] New Drug Approval and Acceptance - This week, four new drugs or new indications received approval, and six new drugs or new indications were accepted for review [3][24]. Clinical Application Approval and Acceptance - This week, 43 new drug clinical applications were approved, and 43 new drug clinical applications were accepted [7][27].

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology sector [7]. Core Insights - The report highlights that the pharmaceutical index increased by 3.29% during the week of November 10-14, 2025, indicating a positive market trend for innovative drugs and flu-related products [11][12]. - The report emphasizes the ongoing investment phase of major products in the pharmaceutical sector, particularly focusing on the BD (Business Development) second act for companies like Sanofi and their collaboration with Pfizer on SSGJ-707 [20][28]. - The report projects a bullish outlook for innovative drugs over the next 5-10 years, suggesting that a new wave of innovation and a bull market for innovative drugs is just beginning, with a focus on "disruption" rather than mere revaluation [14][12]. Summary by Sections 1. Recent Performance - The pharmaceutical sector showed resilience with a 3.29% increase in the index, while innovative drugs and flu treatments performed particularly well [11][12]. - The market is experiencing a rotation between high and low styles, benefiting both consumer and pharmaceutical sectors, especially innovative drugs [12][13]. 2. Investment Strategies - The report outlines specific investment strategies focusing on innovative drugs, including major overseas pharmaceutical companies and small to mid-cap technology revolutions [15][16]. - Key companies to watch include Innovent Biologics, Sanofi, and others in the innovative drug space, as well as those involved in new technologies like brain-computer interfaces and AI in healthcare [15][16]. 3. Future Outlook - The report anticipates continued optimism in the pharmaceutical sector, particularly around innovative drugs, with a focus on overseas major drugs and small-cap technology revolutions [14][15]. - It suggests that the investment landscape will evolve with a focus on leading companies that exhibit characteristics of leadership, disruption, and seriousness in their operations [14]. 4. Clinical Development Highlights - Pfizer's global clinical development plan for SSGJ-707 was disclosed, marking a significant milestone for Sanofi, with a $1.25 billion upfront payment for the collaboration [17][20]. - The report notes that the clinical trial phase for SSGJ-707 is just beginning, which is expected to catalyze further stock price increases for Sanofi [28][20]. 5. Sector Performance Comparison - The report compares the performance of the innovative drug index against the broader pharmaceutical index and the CSI 300 index, noting that the innovative drug index has outperformed both [31][32]. - The innovative drug index has increased by 30.65% since the beginning of 2025, indicating strong market interest and performance [32].

Investment Rating - The report maintains an "Outperform" rating for the Hong Kong stock market [4] Core Insights - The Hong Kong stock market has shown a balanced increase across all styles, with the innovative drug sector leading the gains [1] - The Hang Seng Index increased by 1.3%, with the Hang Seng Composite Index also rising by 1.3% [1] - The report highlights a significant divergence in performance among major concept indices, with the Hang Seng Biotechnology Index rising by 7.0% and the Hang Seng Internet Index declining by 2.0% [1] Summary by Sections Market Performance - The Hang Seng Index's valuation increased by 1.1% to 12.2x, while the Hang Seng Composite Index's valuation rose by 1.3% to 12.1x [2] - The report notes that 20 industries saw an increase in valuation, with notable rises in Steel (+14.0%), Agriculture (+7.4%), Real Estate (+6.8%), and Pharmaceuticals (+6.2%) [2] Earnings Expectations - The earnings per share (EPS) for the Hang Seng Index increased by 0.4% compared to the previous week [3] - The report indicates that 18 industries experienced upward revisions in EPS, with the most significant increases in Electric Power Equipment and New Energy (+4.3%) and Construction (+1.8%) [3]

以下文章来源于数据宝 ，作者刘俊伶 本周（11月10日至14日）港股市场主要股指涨跌不一，恒生指数累计上涨1.26%，恒生科技指数下跌0.42%，恒生中 国企业指数上涨1.41%。 据证券时报·数据宝统计，本周南向资金合计成交净流入247.73亿港元，环比下降35.95%， 已连续26周净流入。 从本周上榜每日前十大活跃个股名单来看，共有17只个股上榜， 阿里巴巴-W 本周港股通成交总额最高，达到 489.19亿港元， 中芯国际、腾讯控股 港股通买卖总额均超过200亿港元。 从成交净买入金额来看，大型科技股本周获南向资金买卖不一， 小米集团-W 本周获南向资金净买入金额最高，达 到43.32亿港元，已连续两周居于净买入首位，上周成交净买入43.11亿港元。小米集团 -W9月26日以来走势明显下 跌，累计跌幅近三成。 腾讯控股 本周获南向资金净买入金额8.58亿港元。 阿里巴巴-W、美团-W 遭到南向资金减持，分别净卖出24.79亿港 元、1.92亿港元。 数据宝 . 数据宝——证券时报智能原创新媒体，中国股市大数据新媒体领先品牌，依托证券时报财经数据库和证监会指定信 息披露媒体的权威信息，让您用手机也能从海量 ...

A-share Market Valuation - The current PE (TTM) for the A-share market is 17.45, with a historical average of 26.03, indicating a significant undervaluation[7] - The PE (TTM) for the Shanghai Composite Index is 14.37, while the CSI 300 is at 13.45, both below historical averages[9] - The contribution of earnings and valuation changes to index performance shows that the Shanghai Composite Index has a current value change rate of 16.64%[13] Hong Kong Market Valuation - The Hang Seng Index has a current PE (TTM) of 12.05, with a historical maximum of 22.67 and a minimum of 7.36[64] - The Hang Seng Technology Index shows a current PE of 22.47, indicating a relatively high valuation compared to other sectors[64] US Market Valuation - The S&P 500 has a current PE (TTM) of 28.67, with a historical maximum of 41.99 and a minimum of 11.21, suggesting a premium valuation[86] - The NASDAQ Index currently stands at a PE of 41.09, reflecting a high growth expectation in the tech sector[86] Sector-Specific Insights - Non-bank financials, food and beverage, and non-ferrous metals sectors in A-shares are currently at historically low PE levels, while sectors like computing and automotive are at high PE levels[24] - In the Hong Kong market, the healthcare sector has a median PE of 52.91, indicating strong growth expectations[75] Risk Factors - Potential risks include policy effectiveness falling short of expectations, corporate earnings not meeting forecasts, and significant market volatility[107]

今天港股延续强势，特别是临近尾盘的拉升，截至收盘恒生指数上涨0.56%。恒生医疗涨幅居前，大消 费、恒生科技、互联网等涨幅居前，银行相对弱势。 互联网尾盘异动，直线拉升，其中阿里巴巴大涨3.32%，地平线机器人上涨1.32%，网易、商汤、美团 等股均有不错表现。 银行股冲高回落，盘中虽有反弹，但力度有限。其中重庆农村商业银行下跌1.19%，农业银行下跌 1.1%，大新金融、民生银行、邮储银行等股均小幅收跌；中国银行、汇丰银行、中信银行等股逆势小 涨。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生医疗高开高走强势爆发，截至收盘大涨3.69%，其中三生制药大涨10.18%，百济神州上涨7.71%， 生物制药上涨6.5%，信达生物上涨5.51%，翰森制药上涨4.85%。 大消费高开高走表现亮眼，其中石药集团上涨3.79%，药明生物上涨3.36%，阿里巴巴上涨3.32%，康方 生物上涨3.23%，创科实业上涨3.02%，比亚迪股份上涨2.29%。 ...

Core Insights - Sanofi Pharmaceutical (01530.HK) has been included in Forbes' "Top 50 Innovative Companies in China 2025," marking it as one of the eight pharmaceutical companies on the list [1] - The evaluation criteria for the list include innovation capability (R&D investment and independent intellectual property), corporate governance, growth potential, market advantages driven by innovation, and social image [1] - This recognition highlights the company's sustained innovation resilience and industry leadership, reflecting the Chinese biopharmaceutical industry's shift towards global value chain leadership through innovation [1] Company Strategy - The company has consistently prioritized innovation as its core development strategy, leveraging opportunities in the high-quality development phase of China's innovative pharmaceuticals [1] - It has made forward-looking investments in cutting-edge fields, launching several self-innovated biological drugs that meet patient needs while promoting industry upgrades [1] - By 2025, the company anticipates a concentrated harvest period for its R&D pipeline, with significant clinical breakthroughs in core areas such as oncology and autoimmune diseases [1] International Expansion - The company's internationalization strategy is accelerating, with notable progress in multiple overseas licensing collaborations, indicating a rising global innovative influence [1] - The recognition from the industry and capital markets underscores the high regard for the company's innovation capabilities and strategic direction [1] - As the global pharmaceutical competitive landscape reshapes and Chinese innovative pharmaceutical companies rise, the company is steadily advancing towards becoming an innovative biopharmaceutical enterprise with a foundation in China and a global outlook [1]

Core Insights - The Hong Kong stock market saw a net inflow of 12.887 billion HKD from northbound trading on November 14, with the Shanghai Stock Connect contributing 7.273 billion HKD and the Shenzhen Stock Connect contributing 5.614 billion HKD [1] Group 1: Top Net Buy Stocks - Alibaba-W (09988) received a net inflow of 13.27 billion HKD, with a total buy amount of 35.87 billion HKD and sell amount of 22.61 billion HKD [2] - Tencent (00700) had a net inflow of 10.71 billion HKD, with total buy and sell amounts of 29.08 billion HKD and 18.38 billion HKD respectively [2] - SMIC (00981) saw a net inflow of 6.64 billion HKD, with total buy and sell amounts of 21.65 billion HKD and 15.01 billion HKD respectively [2] Group 2: Notable Company Developments - Alibaba has secretly launched the "Qianwen" project, aiming to create a personal AI assistant app that competes with ChatGPT, with significant application during the Double 11 shopping festival [5] - Tencent's third-quarter performance exceeded expectations, driven by stable growth across major business segments, with AI playing a crucial role in advertising and gaming [5] - SMIC reported third-quarter revenue of 2.4 billion USD, a year-on-year increase of 10% and a quarter-on-quarter increase of 8%, surpassing market expectations [6] Group 3: Other Notable Stocks - Xpeng Motors (09868) received a net inflow of 2.56 billion HKD, with expectations of profitability starting in Q4 and significant AI-driven growth projected for 2026-2027 [6] - China Life (02628) faced a net outflow of 2.61 billion HKD, while China Mobile (00941) saw a net outflow of 579.6 million HKD [7]

据统计，南下资金已连续13日净买入小米，共计95.2684亿港元；连续2日净买入阿里，共计36.32亿港 元。(格隆汇) 格隆汇11月14日｜南下资金今日净买入港股128.87亿港元。其中： 净买入阿里巴巴-W 22.57亿、腾讯控股21.68亿、中芯国际8.04亿、小米集团-W 6.11亿、小鹏汽车-W 4.67亿； 净卖出盈富基金62.27亿、中国人寿2.61亿、泡泡玛特2.36亿、三生制药1.74亿。 | 阿里巴巴-W | -4.4% | 13.27 | 58.48亿 | 阿里巴巴-W | -4.4% | 9.30 | 30.81亿 | | --- | --- | --- | --- | --- | --- | --- | --- | | 腾讯控股 | -2.3% | 10.71 | 47.46 Z | 中心国际 | -2.8% | 1.40 | 25.39 Z | | 中心同际 | -2.8% | 6.64 | 36.66 Z | 腾讯控股 | -2.3% | 10.97 | 22.55 Z | | 小米集团-W | -2.6% | 6.71 | 18.66 Z | 小米集团-W | -2.6% | ...

Market Overview - The A-share market showed weakness today, influenced by a drop of over 2% in the Nasdaq, with the Shanghai Composite Index closing at 3990.49 points, down 0.97% [1] - The Shenzhen Component fell by 1.93%, and the ChiNext Index dropped by 2.82%, with more than 3300 stocks declining [1] - Trading volume in both markets was below 2 trillion yuan, indicating a lack of activity [1] Sector Performance - Only sectors such as oil and petrochemicals, real estate, banking, and pharmaceuticals showed resilience, while other sectors, particularly AI, communications, and chips, experienced significant declines [1] - The recent fluctuations in the global market have led to a cautious sentiment among domestic investors, raising concerns about whether A-shares will follow the downward trend of overseas markets [1][2] Economic Indicators - Key credit indicators like social financing have shown mediocre performance, indicating a lag in the recovery of confidence in the real economy [5] - In October, new RMB loans amounted to 220 billion yuan, a decrease of 280 billion yuan year-on-year, while social financing increased by 815 billion yuan, down 597 billion yuan year-on-year [5] Investment Sentiment - The current market sentiment is influenced by short-term risk preferences and trading emotions, with a belief that domestic market logic will eventually prevail [2][4] - The ongoing economic stabilization and supportive policies are expected to provide a foundation for valuation levels, suggesting that recent pullbacks could present buying opportunities [4] AI and Innovation Sector - The AI sector faces uncertainties regarding revenue contributions and high capital expenditures, with many companies still in the investment phase and struggling to achieve stable profitability [6] - The introduction of AI in drug discovery and development is seen as a significant opportunity, with potential for increased efficiency and reduced costs in the pharmaceutical industry [12][13] Gold Market - The gold market has shown strong performance compared to equity markets, with recent geopolitical tensions and economic uncertainties driving demand for gold as a safe-haven asset [15][16] - The long-term outlook for gold remains positive due to systemic risks, including inflation and geopolitical tensions, which are expected to support gold prices [16]